Relief Therapeutics Holding SA, a biopharmaceutical company, announced that its wholly owned subsidiary, APR Applied Pharma Research SA (APR), has executed a definitive agreement with Meta Healthcare Ltd. (Meta), acquiring the worldwide rights, except for the United Kingdom (UK), for a novel dosage form of a prescription drug already approved by the US Food and Drug Administration (FDA) and intended for the treatment of patients with phenylketonuria (PKU). This improved product is expected to improve patient acceptance and compliance. Financial terms of the agreement were not disclosed. As previously announced, under the terms of the agreement, Meta will provide the technology transfer package and Relief will conduct clinical studies, manufacturing, regulatory submission and commercialization in the US and EU.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!